Transactions in connection with share buy-back program
Announcement
A.P. Møller - Mærsk A/S – Transactions in connection with share buy-back program
On 5 May 2021, A.P. Møller - Mærsk A/S (the “Company”) announced a share buy-back program of up to DKK 32bn (around USD 5bn) to be executed over a period of two years. On 12 August 2022 the Company announced an increase in the current share buy-back program from DKK 32bn (around USD 5bn) to DKK 39.3bn (around USD 6bn).
As announced on 3 November 2022, during the third phase of the program running from 3 November 2022 up to 3 May 2023, the Company will buy back A and B shares for an amount of up to DKK 11bn. The third phase of the share buy-back program will be executed under EU Commission Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (the “Safe Harbour Regulation”).
The following transactions have been made under the program in the period Monday March 6, 2023 to Friday March 10, 2023:
| Number of A shares | Average purchase price A shares, DKK | Transaction value, A shares, DKK | |
| Accumulated, last announcement (market and A.P. Møller Holding A/S) | 274,570 | 4,645,974,082 | |
| 6 March 2023 | 120 | 16,756.8333 | 2,010,820 |
| 7 March 2023 | 200 | 16,422.2500 | 3,284,450 |
| 8 March 2023 | 100 | 16,084.5000 | 1,608,450 |
| 9 March 2023 | 197 | 15,985.6853 | 3,149,180 |
| 10 March 2023 | 500 | 15,704.9600 | 7,852,480 |
| Total 6-10 March Friday | 1,117 | 17,905,380 | |
| Bought from A.P. Møller Holding A/S* | 1,185 | 16,030.3677 | 18,995,986 |
| Accumulated in third phase of the program (market and A. P. Møller Holding A/S) | 89,984 | 1,348,120,565 | |
| Accumulated under the program (market and A. P. Møller Holding A/S) | 276,872 | 4,682,875,448 | |
| Number of B shares | Average purchase price B shares, DKK | Transaction value, B shares, DKK | |
| Accumulated, last announcement (market, A.P. Møller Holding A/S and the Foundation) | 1,185,860 | 21,031,606,180 | |
| 6 March 2023 | 478 | 16,984.4247 | 8,118,555 |
| 7 March 2023 | 802 | 16,626.2469 | 13,334,250 |
| 8 March 2023 | 400 | 16,279.1375 | 6,511,655 |
| 9 March 2023 | 796 | 16,166.6394 | 12,868,645 |
| 10 March 2023 | 2,000 | 15,873.2050 | 31,746,410 |
| Total 6-10 March Friday | 4,476 | 72,579,515 | |
| Bought from A.P. Møller Holding A/S* | 3,589 | 16,215.4813 | 58,197,363 |
| Bought from the Foundation* | 1,131 | 16,215.6494 | 18,339,899 |
| Accumulated in third phase of the program (market, A. P. Møller Holding A/S and the Foundation) | 361,080 | 5,516,764,940 | |
| Accumulated under the program (market, A. P. Møller Holding A/S and the Foundation) | 1,195,056 | 21,180,722,957 |
*) According to separate agreements, A.P. Møller Holding A/S and A.P. Møller og Hustru Chastine Mc-Kinney Møllers Familiefond (the Foundation) participates on a pro rata basis to the shares purchased in the share buy-back program.
Page 1 of 2
With the transactions stated above, the Company owns a total of 245,040 A shares and 1,061,711 B shares as treasury shares, corresponding to 6.99% of the share capital.
Details of each transaction are included as appendix.
Copenhagen, 13 March 2023
Contact persons:
Head of Investor Relations, Sarah Spray, tel. +45 3147 4170
Head of Media Relations, Jesper Løv, tel. +45 6114 1521
Page 2 of 2
Attachments
- Announcement - Transactions in connection with share buy-back program - week 10 2023
- Daily transactions in connection with share buy-back program - week 10
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CNH Industrial: Periodic Report on a third $50 million tranche of $300 million Buyback Program29.3.2023 22:30:00 CEST | Press release
London, March 29, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that under a third $50 million tranche (the “Third Tranche”) in the framework of its $300 million common share buyback program, the Company completed transactions in the period March 20, 2023 to March 24, 2023, reported in aggregate, as set forth in the table below. After the purchases announced today and considering those previously executed under the Third Tranche, the total invested amount is approximately €20,017,834.02 ($21,418,144.90) for a total amount of 1,496,705 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) excluding fees(€)(€)($) March 20, 2023 139,705 12.9545 1,809,808.42 1,939,571.69 March 22, 2023 183,000 13.6446 2,496,961.80 2,692,973.30 March 23, 2023 256,000 13.4840 3,451,904.00 3,755,326.36 March 24, 2023 262,000 13.3041 3,485,674.20 3,745,356.93 840,705-11,244,348.4212,133,228.28 As of March
Forløb af Lollands Banks generalforsamling den 29. marts 2023.29.3.2023 22:23:38 CEST | pressemeddelelse
Vedhæftet ovennævnte selskabsmeddelelse. Vedhæftet fil Københavns Fondsbørs forløb generalforsamling 2023
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons29.3.2023 22:19:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) -In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The vesting of the restricted stock units granted to Jan G. J. van de Winkel and Anthony Pagano will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. About Genmab Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab29.3.2023 22:10:21 CEST | Press release
Company Announcement COPENHAGEN, Denmark; March 29, 2023 –Genmab A/S (Nasdaq:GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met to constitute itself. Ms. Deirdre P. Connelly was appointed Chair and Ms. Pernille Erenbjerg was appointed Deputy Chair. It was decided to grant90,054restricted stock units to members of managementand employees of the Company and the Company’s subsidiaries and16,276warrants to the employees of the Company andthe Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equa
US healthcare executive Dr. Ninfa Saunders, DHA, MVA, MSN, FACHE and other Board members to be nominated at general meeting; Chris Lindop not standing for re-election.29.3.2023 22:02:33 CEST | Press release
March 29, 2023 Announcement no. 2 US healthcare executive Dr. Ninfa Saunders, DHA,MVA, MSN, FACHEand other Board members to be nominated at general meeting; Chris Lindop not standing for re-election. COPENHAGEN, DENMARK and BOSTON, MA, USA, March 29, 2023, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (BioPorto or Company) (CPH:BIOPOR) announces that Chris Lindop, Chairman of the Board of Directors, has for personal reasons decided not to stand for re-election at the upcoming ordinary general meeting. The Board plans to appoint current Vice Chairman, John McDonough, as the new Chairman following the AGM on April 27, 2023. “I am proud to have helped shepherd BioPorto through this period of significant change and opportunity,” said Mr. Lindop. “I am very confident in the Board, Management, and entire team as they commercialize NGAL tests for Acute Kidney Injury (AKI) in Europe and pursue approval of the first authorized AKI biomarker in the US.” The Board also announces that